Anti-legalization group, Drug Watch International, has requested that the U.S. Food and Drug Administration (FDA) to place marijuana and its derivatives on a list of restricted substances that are not “generally recognized as safe and effective.”

The director of the FDA’s Center for Drug Evaluation, Janet Woodcock, stated in a letter to the group that the move is “not necessary for the protection of public health.”

It was last December that the group had filed a petition with its requesting and wrote that the move would “send an industry-wide warning to the estimated 33,000 marijuana businesses in the U.S., many of which are making unsupported medical claims for marijuana and THC drug products sold as ‘medical marijuana.'”

The organization also said the move would “reduce or end the ability of [over-the-counter] sellers of these drugs to assert and advertise unsupported medical claims for their products.”

It stated, “It would immediately make such claims unlawful and subject the sponsors to regulatory action, including injunctive seizure of mislabeled and misbranded drugs, as well as other potential sanctions permitted under the [Food, Drug and Cosmetic Act].”

The FDA replied that it “already has adequate authority to remove unapproved new OTC drugs containing marijuana or THC from the market.”


Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

We’re Going Live for the High Times Cannabis Cup New Mexico: People’s Choice Edition 2023
22 June 2023
Minnesota Lawmakers to Introduce Marijuana Legalization Bill
03 February 2021
Illinois Legal Marijuana Sales Hit Record in January
06 February 2021